<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nana-Leventaki, E.</style></author><author><style face="normal" font="default" size="100%">Nana, M.</style></author><author><style face="normal" font="default" size="100%">Poulianitis, N.</style></author><author><style face="normal" font="default" size="100%">Sampaziotis, D.</style></author><author><style face="normal" font="default" size="100%">Perrea, D.</style></author><author><style face="normal" font="default" size="100%">Sanoudou, D.</style></author><author><style face="normal" font="default" size="100%">Rontogianni, D.</style></author><author><style face="normal" font="default" size="100%">Malliaras, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cardiosphere-Derived Cells Attenuate Inflammation, Preserve Systolic Function, and Prevent Adverse Remodeling in Rat Hearts With Experimental Autoimmune Myocarditis</style></title><secondary-title><style face="normal" font="default" size="100%">J Cardiovasc Pharmacol TherJ Cardiovasc Pharmacol TherJ Cardiovasc Pharmacol Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Journal of cardiovascular pharmacology and therapeutics</style></alt-title><short-title><style face="normal" font="default" size="100%">Journal of cardiovascular pharmacology and therapeuticsJournal of cardiovascular pharmacology and therapeutics</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Ventricular Function, Left</style></keyword><keyword><style  face="normal" font="default" size="100%">*Ventricular Remodeling</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Autoimmune Diseases/immunology/pathology/physiopathology/*prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Fibrosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mycobacterium tuberculosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocarditis/immunology/pathology/physiopathology/*prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocardium/immunology/pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Myosins</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats, Inbred Lew</style></keyword><keyword><style  face="normal" font="default" size="100%">Spheroids, Cellular/*transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Stem Cell Transplantation/*methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Systole</style></keyword><keyword><style  face="normal" font="default" size="100%">T-Lymphocytes/immunology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">24</style></volume><pages><style face="normal" font="default" size="100%">70-77</style></pages><isbn><style face="normal" font="default" size="100%">1940-4034 (Electronic)1074-2484 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cardiosphere-derived cells (CDCs) have yielded promising efficacy signals in early-phase clinical trials of ischemic and nonischemic cardiomyopathy. The potential efficacy of CDCs in acute myocarditis, an inflammatory cardiomyopathy without effective therapy, remains unexplored. Given that CDCs produce regenerative, cardioprotective, anti-inflammatory, and anti-fibrotic effects (all of which could be beneficial in acute myocarditis), we investigated the efficacy of intracoronary delivery of CDCs in a rat model of experimental autoimmune myocarditis. METHODS: Lewis rats underwent induction of experimental autoimmune myocarditis by subcutaneous footpad injection of purified porcine cardiac myosin supplemented with Mycobacterium tuberculosis on days 1 and 7. On day 10, rats were randomly assigned to receive global intracoronary delivery of 500 000 CDCs or vehicle. Global intracoronary delivery was performed by injection of cells or vehicle into the left ventricular (LV) cavity during transient occlusion of the aortic root. Rats were euthanized 18 days after infusion. Cardiac volumes and systolic function were assessed by serial echocardiography, performed on days 1, 10, and 28. Myocardial inflammation, T-cell infiltration, and cardiac fibrosis were evaluated by histology. RESULTS: Experimental autoimmune myocarditis was successfully induced in 14/14 rats that completed follow-up. Left ventricular ejection fraction (LVEF) and volumes were comparable on days 1 and 10 between groups. CDC infusion resulted in increased LVEF (81.5% +/- 3% vs 65.4% +/- 8%, P &lt; .001) and decreased LV end-systolic volume (43 +/- 15 vs 100 +/- 24 muL, P &lt; .001) compared to placebo administration at 18 days post-infusion. Cardiosphere-derived cell infusion decreased myocardial inflammation (7.4% +/- 7% vs 20.7% +/- 4% of myocardium, P = .007), cardiac fibrosis (16.6% +/- 13% vs 38.1% +/- 3% of myocardium, P = .008), and myocardial T-cell infiltration (30.4 +/- 29 vs 125.8 +/- 49 cells per field, P = .005) at 18 days post-infusion compared to placebo administration. CONCLUSION: Intracoronary delivery of CDCs attenuates myocardial inflammation, T-cell infiltration, and fibrosis while preventing myocarditis-induced systolic dysfunction and adverse remodeling in rats with experimental autoimmune myocarditis.</style></abstract><accession-num><style face="normal" font="default" size="100%">30060693</style></accession-num><notes><style face="normal" font="default" size="100%">Nana-Leventaki, ENana, MPoulianitis, NSampaziotis, DPerrea, DSanoudou, DRontogianni, DMalliaras, Keng2018/08/01 06:00J Cardiovasc Pharmacol Ther. 2019 Jan;24(1):70-77. doi: 10.1177/1074248418784287. Epub 2018 Jul 30.</style></notes><auth-address><style face="normal" font="default" size="100%">1 Third Department of Cardiology, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.2 Department of Pathology, Evangelismos Hospital, Athens, Greece.3 Laboratory for Experimental Surgery and Surgical Research &quot;N.S. Christeas&quot;, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.4 Molecular Biology Division, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.5 Fourth Department of Internal Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.</style></auth-address></record></records></xml>